Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2016. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR) or connected persons, specifically regarding the GlaxoSmithKline Share Value Plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the fair market value of American Depositary Shares (ADS) used for tax withholding, which was $39.14 per ADS (closing price on February 26, 2016).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction where 1,256 ADSs were withheld to meet tax liabilities following the vesting of a 2013 award under the 2009 Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of a share transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Type: Withholding of shares to meet tax liabilities upon vesting.
- Individual Involved: Dr. K. Slaoui (Connected Person of Executive Director Dr. M. Slaoui).
- Shares Withheld: 1,256 ADSs.
- Valuation Date: February 26, 2016.
- Share Price: $39.14 per ADS.
- Notification Date: February 29, 2016.